Biologics in atopic dermatitis;Biologika bei atopischer Dermatitis

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 3, 2012, Pages 174-179

  Taïeb, Alain ^a   Seneschal, Julien ^a   Mossalayi, M Djavad ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

atopic dermatitis; biologics; treatment

Indexed keywords

ALEFACEPT; ALLERGEN; BIOLOGICAL PRODUCT; EFALIZUMAB; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; RITUXIMAB; THROMBOPLASTIN;

ATOPIC DERMATITIS; B LYMPHOCYTE; CELL CLONE; CHRONIC INFLAMMATION; EPIDERMIS; HUMAN; IMMUNE RESPONSE; PRURITUS; REGULATORY MECHANISM; REVIEW; SYSTEMIC THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AGENTS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS;

EID: 84858318213     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2011.07760.x     Document Type: Review

References (28)

1. Brun-Strang C, Taïeb A,. Management and socio economic impact of atopic dermatitis in France: the Elipanel study. Value in Health 2003; 6: 784.
2. Tanei R,. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets 2009; 8 (5): 398-404.
3. Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, Ocampo-Candiani J, Cox M, Langeraar J, Simon JC,. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-32. (Pubitemid 43946465)
4. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N,. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90. (Pubitemid 32735398)
5. Andres C, Belloni B, Mempel M, Ring J,. Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep 2008; 8: 179-80.
6. Krathen RA, Hsu S,. Failure of omalizu-mab for the treatment of severe adult atopic eczema. J Am Acad Dermatol 2005; 53: 338-40. (Pubitemid 40979597)
7. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P,. Omalizumab-an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011; 66 (2): 303-5.
8. Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N,. Alefacept (lymphocyte function asso-ciatedmolecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008; 122: 423-4.
9. Moul DK, Routhouska SB, Robinson MR, Korman NJ,. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008; 58: 984-9.
10. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, Simpson E,. Efalizumab for severe ato-pic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007: 56: 222-7. (Pubitemid 46074243)
11. Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T,. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010; 24: 837-9.
12. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M,. Infliximab in the treatment of moderate to severe Atopic eczema. J Am Acad Dermatol 2005; 53: 522-8.
13. Jiang H, Harris MB, Rothman P,. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000; 105: 1063-70. (Pubitemid 30418781)
14. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM,. Efficacy of soluble Il-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963-70. (Pubitemid 32523334)
15. Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J,. Use of an anti-interleukin-5 antibody in the hy-pereosinophilic syndrome with eosino-philic dermatitis. N Eng J Med 2003; 349: 2334-9. (Pubitemid 37521232)
16. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plötz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS,. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic eczema. Allergy 2005; 60: 693-6. (Pubitemid 40562479)
17. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU,. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121: 122-8.
18. Taïeb A,. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis 1999; 41: 177-80. (Pubitemid 29427906)
19. Palmer CN, Irvine AD, Terron-Kwiat-kowski A, Zhao Y, Liao H, Lee S P, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukho-padhyay S, McLean WH,. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
20. Nair R P, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, Schreiber S, Kabelitz D, Lim HW, Voorhees JJ, Christophers E, Elder JT, Weichenthal M,. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008; 128: 1653-61. (Pubitemid 351847381)
21. Oyoshi MK, Murphy GF, Geha RS,. Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitiza-tion with protein antigen. J Allergy Clin Immunol 2009; 124: 485-93.
22. Milner JD, Brenchley JM, Laurence A, Freeman A F, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC,. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hy-per-IgE syndrome. Nature 2008; 452: 773-6. (Pubitemid 351521078)
23. Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H, Ring J, Traidl-Hoffmann C, Albanesi C, Cavani A,. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009; 123: 59-66.
24. Buddenkotte J, Steinhoff M,. Pathophy-siology and therapy of pruritus in allergic and atopic diseases. Allergy 2010; 65 (7): 805-21.
25. Venereau E, Diveu C, Grimaud L, Ravon E, Froger J, Preisser L, Danger Y, Maillasson M, Garrigue-Antar L, Jacques Y, Chevalier S, Gascan H,. Definition and characterization of an inhibitor for interleukin-31. J Biol Chem 2010; 285: 14955-63.
26. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, Dubus P, Hovnanian A,. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lym-phopoietin expression in Netherton syndrome. J Exp Med 2009; 206: 1135-47.
27. Zhang Z, Hener P, Frossard N, Kato S, Metzger D, Li M, Chambon P,. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci U S A. 2009; 106: 1536-41.
28. Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R,. Low-dose cy-closporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 2009; 64: 1588-96.